Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study

Journal of Thrombosis and Thrombolysis

Volumn 27, Issue 1, 2009, Pages 48-56

  Zyl, Louis T ^a   Lespérance, Francois ^b,c   Frasure Smith, Nancy ^b,c,d   Malinin, Alex I ^e   Atar, Dan ^g,h   Laliberté, Marc André ^b,c   Serebruany, Victor L ^e,f  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e HeartDrug Research Laboratories   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g AKER UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

Author keywords

Acute coronary syndromes; Biomarkers; Citalopram; Clinical trial; Depression; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA THROMBOGLOBULIN; BIOLOGICAL MARKER; CITALOPRAM; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPNOTIC AGENT; INTERCELLULAR ADHESION MOLECULE 1; LONG ACTING DRUG; NITRIC ACID DERIVATIVE; NITRIC OXIDE; PADGEM PROTEIN; PLACEBO;

ADULT; ANXIETY DISORDER; ARTICLE; CANADA; CELL ACTIVITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HAMILTON SCALE; HEART INFARCTION; HUMAN; HUMAN CELL; HYPERTENSION; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ASPIRIN; BETA-THROMBOGLOBULIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; CITALOPRAM; COMORBIDITY; CORONARY DISEASE; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; NITRIC OXIDE; P-SELECTIN; PLATELET AGGREGATION INHIBITORS; PSYCHOTHERAPY; SEROTONIN UPTAKE INHIBITORS; TICLOPIDINE; YOUNG ADULT;

EID: 60749096939     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0189-3     Document Type: Article

References (60)

1. Glassman AH, Shapiro PA (1998) Depression and the course of coronary artery disease. Am J Psychiatry 155:4-11
2. Musselman DL, Evans DL, Nemeroff CB (1998) The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry 55:580-592
3. Smith TW, Ruiz JM (2002) Psychosocial influences on the development and course of coronary heart disease: Current status and implications for research and practice. J Consult Clin Psychol 70:548-568
4. Lesperance F, Frasure-Smith N, Juneau M, Theroux P (2000) Depression and 1-year prognosis in unstable angina. Arch Intern Med 160:1354-1360
5. Lesperance F, Frasure-Smith N, Talajic M, Bourassa MG (2002) Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 105:1049-1053
6. Rumsfeld JS, Jones PG, Whooley MA, Sullivan MD, Pitt B, Weintraub WS et al (2005) Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am Heart J 150:961-967
7. Wassertheil-Smoller S, Shumaker S, Ockene J, Talavera GA, Greenland P, Cochrane B et al (2004) Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med 164:289-298
8. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S et al (1996) Exaggerated platelet reactivity in major depression. Am J Psychiatry 153:1313-1317
9. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA (2005) Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol 46:656-659
10. Kim CK, Mcgorray SP, Bartholomew BA, Marsh M, Dicken T, Wassertheil-Smoller S et al (2005) Depressive symptoms and heart rate variability in postmenopausal women. Arch Intern Med 165:1239-1244
11. Glassman AH, Roose SP, Bigger JT Jr (1993) The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 269:2673-2675
12. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT Jr (1998) Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 155:660-665
13. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG et al (1998) Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279:287-291
14. Keller MB (2000) Citalopram therapy for depression: A review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry 61:896-908
15. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr et al (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288:701-709
16. Cohen HW, Gibson G, Alderman MH (2000) Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 108:2-8
17. Sauer WH, Berlin JA, Kimmel SE (2001) Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 104:1894-1898
18. Rasmussen A, Hindberg I, Mellerup E (2000) Does sertraline-induced platelet dysfunction protect stroke patients against cardiovascular comorbidity? Int J Neuropsychopharmacol 3:S372
19. Serebruany VL, Gurbel PA, O'Connor CM (2001) Platelet inhibition by sertraline and N-desmethylsertraline: A possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 43:453-462
20. Serebruany VL, O'Connor CM, Gurbel PA (2001) Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am J Cardiol 87:1398-1400
21. Atar D, Malinin A, Takserman A, Pokov A, Van Zyl LT, Tanguay JF et al (2006) Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans. J Clin Psychopharmacol 26:172-177
22. Lesperance F, Frasure-Smith N, Koszycki D, Laliberté M-A, Van Zyl LT, Baker B et al (2007) Effects of citalopram and interpersonal psychotherapy on depression in coronary artery disease patients: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE). JAMA 297:367-379
23. Kaplan KL, Owen J (1981) Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 57:199-202
24. Pumphrey CW, Dawes J (1982) Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction. Am J Cardiol 50:1258-1261
25. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L et al (2001) Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104:1336-1342
26. Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, Walsh M (2001) Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 85:623-627
27. Valles J, Santos MT, Aznar J, Martinez M, Moscardo A, Pinon M et al (2002) Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: Down-regulation by aspirin ex vivo. Blood 99:3978-3984
28. Tschoepe D, Spangenberg P, Esser J, Schwippert B, Kehrel B, Roesen P et al (1990) Flow-cytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actin status of activated platelets. Cytometry 11:652-656
29. O'Connor CM, Gurbel PA, Serebruany VL (1999) Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 83:1345-1349
30. Gurbel PA, Kereiakes DJ, Dalesandro MR, Bahr RD, O'Connor CM, Serebruany VL (2000) Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. Am Heart J 139:320-328
31. Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142
32. Archer S (1993) Measurement of nitric oxide in biological models. FASEB J 7:349-360
33. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P (1995) Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 125:370-377
34. Chen LY, Mehta JL (1994) Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci 55:1815-1821
35. Goumas G, Tentolouris C, Tousoulis D, Stefanadis C, Toutouzas P (2001) Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis 154:255-267
36. Cerwinka WH, Cooper D, Krieglstein CF, Feelisch M, Granger DN (2002) Nitric oxide modulates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules. Am J Physiol Heart Circ Physiol 282:H1111-H1117
37. Radomski MW, Palmer RM, Moncada S (1990) An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87:5193-5197
38. Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B (2001) Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol 88:196-198, A7
39. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, Van Zyl LT et al (2003) Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 108:939-944
40. Briley MS, Raisman R, Sechter D, Zarifian E, Langer SZ (1980) [3H]-imipramine binding in human platelets: A new biochemical parameter in depression. Neuropharmacology 19:1209-1210
41. Nemeroff CB, Knight DL, Krishnan RR, Slotkin TA, Bissette G, Melville ML et al (1988) Marked reduction in the number of platelet-tritiated imipramine binding sites in geriatric depression. Arch Gen Psychiatry 45:919-923
42. Hrdina PD, Bakish D, Ravindran A, Chudzik J, Cavazzoni P, Lapierre YD (1997) Platelet serotonergic indices in major depression: Up-regulation of 5-HT2A receptors unchanged by antidepressant treatment. Psychiatry Res 66:73-85
43. Schneider LS, Severson JA, Pollock V, Cowan RP, Sloane RB (1986) Platelet monoamine oxidase activity in elderly depressed outpatients. Biol Psychiatry 21:1360-1364
44. Reichborn-Kjennerud T, Lingjaerde O, Oreland L (1996) Platelet monoamine oxidase activity in patients with winter seasonal affective disorder. Psychiatry Res 62:273-280
45. Piletz JE, Zhu H, Madakasira S, Pazzaglia P, Lindsay DC, Goldman N et al (2000) Elevated P-selectin on platelets in depression: Response to bupropion. J Psychiatr Res 34:397-404
46. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS (1997) Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 42:290-295
47. Kuijpers PM, Hamulyak K, Strik JJ, Wellens HJ, Honig A (2002) Beta-thromboglobulin and platelet factor 4 levels in post-myocardial infarction patients with major depression. Psychiatry Res 109:207-210
48. Martinez-Sales V, Vila V, Reganon E, Goberna MA, Ferrando F, Palencia MA et al (1998) Elevated thrombotic activity after myocardial infarction: A 2-year follow-up study. Haemostasis 28:301-306
49. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI (2001) Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104:1533-1537
50. Ikeda H, Nakayama H, Oda T, Kuwano K, Muraishi A, Sugi K et al (1994) Soluble form of P-selectin in patients with acute myocardial infarction. Coron Artery Dis 5:515-518
51. Linkowski P, Mendlewicz J, Leclercq R, Brasseur M, Hubain P, Golstein J et al (1985) The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness. J Clin Endocrinol Metab 61:429-438
52. Steckler T, Holsboer F, Reul JM (1999) Glucocorticoids and depression (Review). Baillieres Best Pract Res Clin Endocrinol Metab 13:597-614
53. Larsson PT, Wallen NH, Hjemdahl P (1994) Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 89:1951-1957
54. Slowik A, Turaj W, Pankiewicz J, Dziedzic T, Szermer P, Szczudlik A (2002) Hypercortisolemia in acute stroke is related to the inflammatory response. J Neurol Sci 196:27-32
55. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J (1996) Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 32:653-658
56. Lara N, Archer SL, Baker GB, Le Melledo JM (2003) Paroxetine-induced increase in metabolic end products of nitric oxide. J Clin Psychopharmacol 23:408-412
57. Chrapko W, Jurasz P, Radomski MW, Archer SL, Newman SC, Baker G et al (2006) Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 31:1286-1293
58. Rapold HJ, Grimaudo V, Declerck PJ, Kruithof EK, Bachmann F (1991) Plasma levels of plasminogen activator inhibitor type 1, beta-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase. Blood 78:1490-1495
59. Kauhanen P, Kovanen PT, Lassila R (2000) Coimmobilized native macromolecular heparin proteoglycans strongly inhibit platelet-collagen interactions in flowing blood. Arterioscler Thromb Vasc Biol 20:E113-E119
60. Leu HB, Charng MJ, Ding PY (2004) A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension. Jpn Heart J 45:623-635